OncoTargets and Therapy (Dec 2016)

Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients

  • Wen X,
  • Lu F,
  • Liu S

Journal volume & issue
Vol. Volume 9
pp. 7425 – 7433

Abstract

Read online

Xiajie Wen,1 Fengmin Lu,1,2 Shuang Liu3 1Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, 2Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, 3Beijing Artificial Liver Treatment and Training Center, Beijing Youan Hospital, Capital Medical University, Beijing, China Abstract: Several previous studies have investigated the association between gene p53 (p53) mutation and the poor outcome of primary liver cancer (PLC) patients; however, the results remain inconsistent. In the present study, p53 mutation in 60 paired tumor and corresponding nontumor tissues derived from a cohort of 60 PLC patients was systematically analyzed. The results showed that p53 mutation was only an independent risk factor for overall survival (OS), not for recurrence-free survival (RFS), and a meta-analysis was performed to verify this. Online databases were searched up to July 1, 2016. Studies about the association between p53 mutation and the postsurgery survival of PLC patients were collected. A total of 988 patients from eight studies were analyzed; among them, 341 (34.51%) patients had p53 mutation. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were 2.03 (1.64, 2.41) and 2.36 (1.31, 3.42) for OS and RFS, respectively. In conclusion, both the cohort study and meta-analysis suggested that the p53 mutation was associated with postsurgery OS in Asian PLC patients. However, the relationship between p53 mutation and recurrence should be confirmed by further studies. Keywords: p53, primary liver cancer, survival, meta-analysis

Keywords